Search Results 231-240 of 15488 for TNF

  1. Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) ≤ 2 weeks prior to registration. Note: Patients who have received acute, low dose, systemic immunosuppressant ...

  2. https://www.mayoclinic.org/spanish_patient_consumer_faq.xml

  3. https://www.mayoclinic.org/arabic_procedure_concepts.xml

  5. ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 - Mayo Clinic

    Received monoclonal antibodies targeting cytokines (e.g., tumor necrosis factor (TNF) inhibitors, anti-IL-1 [e.g., anakinra, canakinumab], anti-IL-6 [e.g. ...

  6. COVID-19 Tests Clinical Trials - Mayo Clinic Research

    Hypothesis: Baseline cytokine (IL-1β, IL-6, IL-4, IL-10, IFN-g and TNF-a) and the immune cellular repertoire (helper/CD4+, cytotoxic/CD8+, T-regulatory ...

  7. A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1. Patients who have received acute, low dose, systemic immunosuppressant ...

  8. Neonatally-Derived Tissues for Biotherapeutic Manufacturing - Mayo Clinic

    About this study. The purpose of this study is to create a shared Mayo Clinic resource for biotherapies derived from various perinatal tissues (umbilical ...

  9. Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis - Mayo Clinic

    * Belimumab, telitacicept, abatacept, TNF-? mAb, immunoglobulins (i.v./s.c.) plasmapheresis * Any other immuno-suppressants (i.v. or oral cyclophosphamide ...

  10. Publications - Michael M. Pham, M.D. - Mayo Clinic

    Intra-articular therapy with methotrexate or tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic review. BMC Musculoskelet Disord. 2021 ...